vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of “Moderate Buy” by Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $53.00.

VTVT has been the subject of several research analyst reports. Evercore initiated coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price objective for the company. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Finally, Zacks Research cut shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th.

vTv Therapeutics Stock Performance

NASDAQ:VTVT opened at $35.08 on Monday. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00. The firm has a 50 day moving average of $33.93 and a 200-day moving average of $35.63. The stock has a market capitalization of $138.22 million, a P/E ratio of -37.72 and a beta of 0.27.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. As a group, analysts forecast that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

Institutional Trading of vTv Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $221,000. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $731,000. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its position in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.